NasdaqGS:STOKBiotechs
Is Stoke Therapeutics’ (STOK) New CSO Appointment Reframing Its Genetic Medicines Innovation Story?
Stoke Therapeutics recently appointed Thomas McCauley, Ph.D., as Chief Scientific Officer, bringing more than 25 years of R&D leadership experience across genetic medicines and rare diseases, and granted him stock options under its 2023 Inducement Plan.
McCauley’s background in building and advancing RNA and genetic medicine platforms may be especially relevant as Stoke seeks to progress its antisense oligonucleotide pipeline in severe genetic disorders.
Next, we’ll examine how adding an...